NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization6,890.16 mln
Float21.00 mln
Earnings Date11/17/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
214
Modest upside
Relative Strength
97
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-18.50
Negative
Dividend Yield
0.00%
No dividend
Business Description
Belite Bio is a San Diego-based drug development company focused on creating treatments for serious eye conditions that currently have few or no effective options. Its most advanced drug, Tinlarebant, is taken by mouth and is currently in Phase 3 trials for patients with Stargardt disease and geographic atrophy, two conditions that cause progressive vision loss. The company is also working on a separate oral drug targeting liver disease, type 2 diabetes, and gout. Founded in 2016, Belite Bio operates as part of Lin Bioscience International Ltd.
